CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]drug
Likely dose
Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04461795
NCT04461795Phase 4Completed
CompareCT.gov

A Multicenter, Open Label Study Assessing the Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

David True·interventional·Posted Jul 8, 2020·Updated Apr 13, 2022

In Brief

A Phase 4 clinical trial evaluating Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY] for Migraine. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

This study is being conducted to evaluate the efficacy and safety of AJOVY (fremanezumab-vfrm) on interictal migraine related burden in adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJul 8, 2020
Enrollment StartDec 1, 2020
Primary CompletionJan 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.0 years ago

Interventions

Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]drug

225 MG/1.5 ML Subcutaneous Solution